Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumabAlexander M. Menzies, Georgina V. Long, Jeffrey A. Sosman et al.|Annals of Oncology|2016Cited by 822
713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: Results from the phase II MoST-CIRCUIT trialOliver Klein, Bo Gao, Matteo S. Carlino et al.|Annals of Oncology|2024Cited by 11
Nivolumab and Ipilimumab in Advanced Mismatch Repair–Deficient/Microsatellite Instability–High Noncolorectal CancersMatteo S. Carlino, Oliver Klein, Bo Gao et al.|JAMA Oncology|2025Cited by 5
282P Nivolumab and ipilimumab combination treatment in advanced intrahepatic cholangiocarcinoma and gallbladder cancerOliver Klein, A. Nagrial, Matteo S. Carlino et al.|Annals of Oncology|2024Cited by 3
Data from Nivolumab and Ipilimumab Combination Treatment in Patients with Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer: Results from the Phase II MoST-CIRCUIT TrialAdnan Nagrial, Oliver Klein, Matteo S. Carlino et al.|Unknown|2026Cited by 0